Press Releases
Otsuka Holdings Announces Collaboration with ReCor Medical for Commercialization of ReCor Medical’s Ultrasound Renal Denervation Technology in Asia
Otsuka Holdings Co Ltd announced the signing of a development and commercialization agreement with ReCor Medical Inc. together with an additional investment. As part of the agreement, Otsuka Holdings. obtained exclusive rights to the commercialization...
Press Releases
Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs
Visionary, up to $2 billion multi-year alliance to focus on development of new gene therapy and gene editing technologies and create a therapeutic platform for a broad range of diseases Biogen to team up with renowned gene therapy...
Press Releases
Immunosup pressant CellCept Obtained Approval for Additional Indication of “Lupus Nephritis”
Chugai Pharmaceutical Co Ltd. announced that it obtained a supplemental approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 13, 2016, for “CellCept®. Capsules 250” and “CellCept® Powder for Oral Suspension 31.8%”...
Press Releases
Chugai Pharmaceutical Co Ltd. to Take Part in “Relay for Life Japan” Using “3D Adventure Experience (Lung Cancer)” to promote awareness of the early...
Chugai Pharmaceutical Co Ltd announced that its co-sponsorship of “Relay for Life Japan” (Organizer: Japan Cancer Society etc.), a charity activity aiming to support cancer patients and their families, and encourage the entire community to confront and conquer cancer...
Press Releases
Pfizer reports Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting
Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies,...
Press Releases
Pfizer Announces Results From Two Phase 3 TRUMENBA Studies At The European Society For Paediatric Infectious Diseases Meeting
Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. ]The two...
Press Releases
EU approves Alprolix (rFIXFc) for the Treatment of Haemophilia B
First Fc Fusion Therapy Approved for haemophilia B in the EU to Provide Extended Protection Against Bleeds Swedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read